fah hospital policy blog

Perspectives on health policy affecting America’s hospitals and the patients we serve.

Category Archives: pharmaceuticals

New Report Shows Impact of Rising Drug Prices and Drug Shortages on Patients and Hospitals

January 15, 2019 | FAH Policy Blog Team

Category: Pharmaceuticals, Research

Today, the Federation of American Hospitals (FAH), the American Hospital Association (AHA), and the American Society of Health-System Pharmacists (ASHP) released a new report finding that continued rising drug prices, as well as shortages for many critical medications, are impacting patient care and putting strains on hospital budgets and operations. The report was prepared based on analysis conducted by NORC at the University of Chicago, an independent research institution.

Read More »

FAH Leader Expresses Opposition to Ruling that Overturns 340B Medicare Regulation

January 02, 2019 | Chip Kahn

Category: Financing, Medicare, Pharmaceuticals

The DC Federal District Court’s ruling to stop reforms to Medicare payment for drugs acquired under the 340B drug discount program is unfortunate because it undermines HHS efforts to cut drug costs and promote fairer payments.

Read More »

FAH Comments on International Pricing Index Model ANPRM

December 21, 2018 | FAH Policy Blog Team

Category: Pharmaceuticals

Today, the FAH commented on the Administration’s International Pricing Index Model for Medicare Part B Drugs Advance Notice of Proposed Rulemaking (ANPRM). The ANPRM signaled the Administration’s interest in testing an Innovation Center model which would dramatically change the manner in which Part B drugs are priced, acquired and paid for in the Medicare program.

Read More »

Groups Urge Congress to Protect Seniors from Rising Drug Prices

November 13, 2018 | FAH Policy Blog Team

Category: Medicare, Pharmaceuticals

The Federation of American Hospitals joined 16 other groups in sending a letter to Congressional leaders today urging them to preserve the actions taken in the Bipartisan Budget Act (BBA) of 2018 to protect seniors and taxpayers from out-of-control drug prices during the upcoming lame duck session of Congress.

Read More »